ASCO 2023 – Merck’s Kelun deal gets its first validation
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.
Asco data suggest that the TROP2 ADC Merck & Co licensed from Kelun is at least as good as Gilead and Astra/Daiichi’s assets.